Dive into groundbreaking studies, experimental protocols, and innovative methodologies shaping chemical biology.
Discover how MS2133, the first DOT1L PROTAC degrader, is revolutionizing leukemia treatment by targeting both enzymatic and scaffolding functions of DOT1L.